Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B-Reference-Cited by-同舟云学术

Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B

Published:2024-03-29 Issue:4 Volume:16 Page:529
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Wang Yong-Hong¹,Tang Hong¹,Chen En-Qiang¹^ORCID

Affiliation:

1. Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China

Abstract

Hepatitis B virus (HBV) infection is a serious global health problem, and chronic HBV infection significantly increases the risk of liver fibrosis, cirrhosis, and even hepatocellular carcinoma in patients. Current first-line therapeutics such as nucleos(t)ide analogues and interferons are unable to completely clear cccDNA, so the vast majority of patients need to take long-term or even lifelong medication. However, long-term virological and biochemical responses can be achieved in some patients after drug withdrawal. Successfully screening these patients with drug withdrawal advantages is difficult. Hepatitis-B-core-related antigen (HBcrAg) is a new HBV serological marker that which can reflect the level and transcription activity of cccDNA in hepatocytes. Therefore, HBcrAg has potential value in guiding patients in drug withdrawal. This review summarizes previous reports on HBcrAg and evaluates the application value of HBcrAg in safe drug discontinuation.

Funder

Clinical Research Incubation Project of West China Hospital of Sichuan University

Publisher

MDPI AG

Link

https://www.mdpi.com/1999-4915/16/4/529/pdf

Reference80 articles.

1. The Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol., 3, 383–403.

2. (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. Lancet Gastroenterol. Hepatol., 8, 879–907.

3. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3740 studies and 231 million people;Liu;Gut,2023

4. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B;Nassal;Gut,2015

5. Chinese Society of Infectious Diseases, Chinese Medical Association (2019). The expert consensus on clinical cure (functional cure) of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi, 27, 594–603.